Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK.

Clin Cancer Res. 2014 Apr 1;20(7):1846-55. doi: 10.1158/1078-0432.CCR-13-2141. Epub 2014 Jan 31.

2.

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ.

Br J Cancer. 2009 Nov 17;101(10):1699-708. doi: 10.1038/sj.bjc.6605381. Epub 2009 Oct 27.

3.

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.

Chang Q, Jorgensen C, Pawson T, Hedley DW.

Br J Cancer. 2008 Oct 7;99(7):1074-82. doi: 10.1038/sj.bjc.6604676. Epub 2008 Sep 16.

4.

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

Caccia D, Miccichè F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I.

Mol Cancer. 2010 Oct 18;9:278. doi: 10.1186/1476-4598-9-278.

5.

Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM.

Sci Transl Med. 2012 May 30;4(136):136ra70. doi: 10.1126/scitranslmed.3003513.

6.

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.

Rebocho AP, Marais R.

Oncogene. 2013 Jun 27;32(26):3207-12. doi: 10.1038/onc.2012.330. Epub 2012 Aug 27.

PMID:
22926515
7.

Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.

Wu Z, Doondeea JB, Gholami AM, Janning MC, Lemeer S, Kramer K, Eccles SA, Gollin SM, Grenman R, Walch A, Feller SM, Kuster B.

Mol Cell Proteomics. 2011 Dec;10(12):M111.011635. doi: 10.1074/mcp.M111.011635. Epub 2011 Sep 28.

8.

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ.

Breast Cancer Res Treat. 2007 Nov;105(3):319-26. Epub 2007 Feb 1.

PMID:
17268817
9.

Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.

Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, Shaw AS.

Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6067-72. doi: 10.1073/pnas.1102554108. Epub 2011 Mar 25.

10.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.

Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.

11.

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J.

Cancer Res. 2008 Jun 15;68(12):4853-61. doi: 10.1158/0008-5472.CAN-07-6787.

12.

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Eustace AJ, Crown J, Clynes M, O'Donovan N.

J Transl Med. 2008 Sep 29;6:53. doi: 10.1186/1479-5876-6-53.

13.

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.

Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902.

14.

Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.

Shi M, Lou B, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J.

Cancer Chemother Pharmacol. 2013 Jul;72(1):35-44. doi: 10.1007/s00280-013-2166-1. Epub 2013 May 28.

PMID:
23712327
15.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
16.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

17.

Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.

Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF.

Cell Death Dis. 2014 Mar 13;5:e1114. doi: 10.1038/cddis.2014.43.

18.

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Buettner R, Mesa T, Vultur A, Lee F, Jove R.

Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169.

19.

Targeting SRC in mucinous ovarian carcinoma.

Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK.

Clin Cancer Res. 2011 Aug 15;17(16):5367-78. doi: 10.1158/1078-0432.CCR-10-3176. Epub 2011 Jul 7.

20.

Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.

Clin Sci (Lond). 2012 Jan;122(1):13-24. doi: 10.1042/CS20110230.

PMID:
21751967
Items per page

Supplemental Content

Write to the Help Desk